- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Menu
Therapeutic Risankizumab antibody from the original Skyrizi® commercial drug.
Showing all 3 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
|---|---|---|---|---|---|---|---|---|---|---|
IL-23 |
Monoclonal Antibody |
Skyrizi® |
150 mg/mL |
yes |
6 mg |
-80°C |
2023.04 |
1.066,00 € |
||
IL-23 |
Monoclonal Antibody |
Skyrizi® |
150 mg/mL |
yes |
6 mg |
-80°C |
2024.03 |
1.066,00 € |
||
IL-23 |
Monoclonal Antibody |
Skyrizi® |
150 mg/mL |
yes |
6 mg |
-80°C |
2024.05 |
1.066,00 € |
| Drug name | Skyrizi® |
| INN | Risankizumab |
| API type | Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody selective to the interleukin (IL)-23 protein produced in Chinese Hamster Ovary cells using recombinant DNA technology. |
| Pharmacotherapeutic group | Immunosuppressants, interleukin inhibitors. |
| ATC code | L04AC18 |
| Target of antibody | IL-23 |
| General function | Risankizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds with high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine without binding to IL-12 and inhibits its interaction with the IL-23 receptor complex. IL-23 is a cytokine that is involved in inflammatory and immune responses. By blocking IL-23 from binding to its receptor, risankizumab inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | In a study of subjects with psoriasis, expression of genes associated with the IL-23/IL-17 axis was decreased in the skin after single doses of risankizumab. Reductions in epidermal thickness, infiltration of inflammatory cells, and expression of psoriatic disease markers were also observed in psoriatic lesions. |
| Original license holder | AbbVie Biotechnology GmbH Knollstrasse 67061 Ludwigshafen Germany |
| Marketing authorisation numbers | EU/1/19/1361/001 |
| Marketing authorisation holder | AbbVie Deutschland GmbH & Co. KG Knollstrasse 67061 Ludwigshafen Germany |
| Name of the manufacturer of the biological active substance | Boehringer Ingelheim Pharma GmbH & Co. KG Birkendorfer Str. 65 88397 Biberach a.d.R. GERMANY and AbbVie Bioresearch Center Inc. 100 Research Drive Worcester MA 01605 USA |
| Name and address of the manufacturer(s) responsible for batch release | AbbVie S.r.l. 148, Pontina Km 52 snc 04011 Campoverde di Aprilia (LT) ITALY and AbbVie Deutschland GmbH & Co. KG Knollstrasse 67061 Ludwigshafen GERMANY |
| Max shelf life | 24 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | Disodium succinate hexahydrate Succinic acid Sorbitol Polysorbate 20 Water for injections |
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany
